Drugs / Warfarin
Warfarin
also known as
Coumadin · Warfarin Sodium · Marevan · Aldocumar · Apo-warfarin · Athrombin · Athrombin-k · Choice · +19 more
Small molecule targets VKORC1
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | COUMADIN | — | 1994-03-31 – 1995-04-28 | fda.gov ↗ |
| Approved | US (FDA) | COUMADIN | — | 1954-06-08 | fda.gov ↗ |
Trials 230 · started per year
today
US approved 1954
1
1
1
2
4
3
5
6
1
6
11
8
8
11
14
11
5
6
8
19
12
11
12
7
9
8
6
11
8
9
6
195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
News releases announcing trial results or a regulatory action · 58
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Janssen Research & Development, LLC | Results Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization jnj.com ↗
Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO®(rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery. |
| 2023-03-06 | Bayer | Results New real world study data on reduced risk of adverse kidney outcomes for Xarelto™ compared to VKA bayer.com ↗
In the XARENO study, Xarelto (rivaroxaban) was associated with a reduced risk of adverse kidney outcomes in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD) compared to vitamin K antagonists. |
| 2022-11-02 | Bristol-Myers Squibb | Results Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022 bms.com ↗
Benefits of Apixaban Over Warfarin are Preserved Independent of Warfarin Time in Therapeutic Range: Insights From the AUGUSTUS Trial* |
| 2021-05-17 | Bayer | Results Large real-world study shows benefit of rivaroxaban in patients with nonvalvular atrial fibrillation with type 2 diabetes bayer.com ↗
Real-world data presented at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21) showed that the oral Factor Xa inhibitor rivaroxaban (Xarelto™) was associated with reduced vascular mortality in patients with nonvalvular atrial fibrillation (NVAF) and comorbid type 2 diabetes (T2D), with fewer bleeding-related hospitalizations versus warfarin. |
| 2019-12-07 | Pfizer | Results Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer pfizer.com ↗
Eliquis was also associated with a lower rate of recurrent VTE (HR: 0.68, 95% CI: 0.52-0.90, p=0.007) and similar rates of major bleeding (HR: 0.73, 95% CI: 0.53-1.0, p=0.051) and CRNM bleeding (HR: 0.89, 95% CI: 0.77-1.04, p=0.145) compared to warfarin. |
| 2019-09-20 | Janssen Research & Development, LLC | Results XARELTO® (rivaroxaban) Reduces Recurrent Blood Clots and Total Medical Costs in Morbidly Obese Patients jnj.com ↗
Notably, patients taking XARELTO®had significantly reduced healthcare resource utilization (HRU) and total medical costs compared to those taking warfarin. |
| 2019-03-19 | Daiichi Sankyo | Results Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation daiichisankyo.com ↗
Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm Association, shows ELIMINATE-AF met primary efficacy and safety objectives, demonstrating low thromboembolic and bleeding event rates[1] |
| 2018-01-16 | Bayer | Results FDA report reaffirms safety profile and effectiveness of Bayer’s Xarelto® in routine clinical practice bayer.com ↗
a lower risk of ischemic stroke and intercranial haemorrhage was associated with the use of rivaroxaban compared to warfarin |
| 2017-11-15 | Daiichi Sankyo | Results New LIXIANA® sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017 daiichisankyo.com ↗
A sub-analysis of the ENGAGE AF-TIMI 48 trial found that edoxaban had even greater reductions in ischaemic events compared to warfarin in patients with atrial fibrillation (AF) and coronary artery disease (CAD) |
| 2017-08-29 | Pfizer | Results Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced findings from a real-world data analysis of the U.S. Humana database, in which treatment with Eliquis® (apixaban) was associated with a significantly lower risk of stroke/systemic embolism and lower rates of major bleeding compared to warfarin in patients aged 65 years and older with non-valvular atrial fibrillation (NVAF). |
| 2017-08-29 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation bms.com ↗ |
| 2017-08-28 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation bms.com ↗ |
| 2017-08-27 | Pfizer | Results Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗
Among non-valvular atrial fibrillation (NVAF) patients, Eliquis ® (apixaban) was associated with a lower risk of stroke/SE and lower rates of major bleeding compared to warfarin for the overall population as well as for each of the selected high-risk patient sub-populations. |
| 2017-03-19 | Boehringer Ingelheim | Results Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation prnewswire.com ↗
In the RE-CIRCUIT trial, uninterrupted PRADAXA significantly reduced the risk of major bleeding complications compared with uninterrupted warfarin. |
| 2017-03-17 | Pfizer | Results Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation pfizer.com ↗
In the analysis, titled Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin among Non-Valvular Atrial Fibrillation Patients in the U.S. Medicare Population , Eliquis ® (apixaban) was associated with a significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin. |
| 2017-03-17 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation bms.com ↗
In this U.S. Medicare database analysis, Eliquis ® (apixaban) was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin |
| 2016-11-14 | Boehringer Ingelheim | Results First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care prnewswire.com ↗
Although treatment guidelines recommend OAC treatment for all NVAF patients at high stroke risk (i.e., CHADS 2 score ≥2), researchers found less than half (41.1 percent) of the study patients were treated with an OAC (warfarin, dabigatran, rivaroxaban or apixaban). |
| 2016-10-21 | Boehringer Ingelheim | Results New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment prnewswire.com ↗
The analysis shows that patients treated with PRADAXA experienced fewer all-cause annual hospitalizations, emergency room (ER) visits and physician office visits, than those treated with warfarin. |
| 2016-08-23 | Pfizer | Results Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 pfizer.com ↗
Patients with Atrial Fibrillation and History of Falls Are at High Risk for Bleeding but Have Less Bleeding with Apixaban than Warfarin: Results from the ARISTOTLE Trial |
| 2015-12-10 | Pfizer | Results AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy pfizer.com ↗
These findings indicate that the favorable benefit-to-risk profile of Eliquis was demonstrated early during treatment for VTE, including the use of a higher Eliquis dose of 10 mg twice daily for the initial seven days. |
| 2015-12-10 | Bristol-Myers Squibb | Results AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy bms.com ↗
The subanalysis demonstrated Eliquis (apixaban) was comparable to conventional therapy |
| 2015-11-09 | Boehringer Ingelheim | Results Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care prnewswire.com ↗
Brigham and Women's Hospital in Boston and Boehringer Ingelheim today announced the results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa® (dabigatran etexilate mesylate) relative to warfarin in routine clinical practice. |
| 2015-05-14 | Janssen Research & Development, LLC | Results New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015 jnj.com ↗ |
| 2015-03-30 | Janssen Research & Development, LLC | Results New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO® Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits jnj.com ↗
A 27 percent reduction in hospital admissions when patients were treated with XARELTO® instead of LMWH and warfarin (p<0.001). |
| 2015-03-16 | Boehringer Ingelheim | Results New Data from Boehringer Ingelheim's GLORIA™-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated prnewswire.com ↗
The most frequently prescribed oral anticoagulants in patients with a CHA 2 DS 2 -VASc score of 2 or higher were vitamin K antagonists (VKAs, e.g., warfarin) |
| 2014-11-18 | Boehringer Ingelheim | Results Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation prnewswire.com ↗
The data also showed a 23 percent reduction in strokes in patients taking PRADAXA compared to warfarin in this pooled analysis of both databases (HR 0.77, CI 0.54-1.09, 62 vs. 69 events). |
| 2014-11-18 | Janssen Research & Development, LLC | Results Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care jnj.com ↗
New data presented today at the American Heart Association (AHA) 2014 Scientific Sessions showed once-daily XARELTO® (rivaroxaban) is associated with significantly fewer hospitalization days and outpatient visits compared to warfarin in patients with non-valvular atrial fibrillation (NVAF). |
| 2014-11-17 | Boehringer Ingelheim | Results U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation prnewswire.com ↗
The risk of major bleeding, the second primary outcome, was 13 percent less with PRADAXA (HR 0.87, CI 0.74-1.02, ER 3.08 vs. 3.70, respectively). |
| 2014-11-03 | Boehringer Ingelheim | Results FDA Study of Medicare Patients Reaffirms Safety and Efficacy Profile of Pradaxa® (dabigatran etexilate mesylate) for NVAF prnewswire.com ↗
The study found no difference in major bleeds or myocardial infarction with PRADAXA compared to warfarin. |
| 2014-09-03 | Daiichi Sankyo | Results Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes daiichisankyo.com ↗
The analysis also compared rates of major bleeding and efficacy outcomes [stroke and systemic embolic events (SEE)] of edoxaban versus warfarin, stratified by dose reduction status. |
| 2014-09-02 | Boehringer Ingelheim | Results ESC Hot Line: Data Reports NVAF Patients Taking Pradaxa® (dabigatran etexilate mesylate) Experienced Slower Decline in Kidney Function Compared to Those on Warfarin prnewswire.com ↗
Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa® (dabigatran etexilate mesylate) compared to warfarin. |
| 2014-09-02 | Janssen Research & Development, LLC | Results New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion jnj.com ↗
In addition, 0.61 percent of patients treated with XARELTO® were also observed to have a major bleeding event compared with 0.81 percent for VKA. |
| 2014-03-27 | Bristol-Myers Squibb | Results In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 bms.com ↗
However, this subanalysis found consistent results for Eliquis versus warfarin in reducing the risk of stroke, regardless of blood pressure control. |
| 2014-03-24 | Daiichi Sankyo | Results Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant daiichisankyo.com ↗
Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials1,2,3,4 |
| 2014-02-21 | Bristol-Myers Squibb | Results In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation bms.com ↗
Eliquis was more effective than warfarin in reducing the risk of stroke and reducing mortality across age groups, and was associated with less major bleeding, less total bleeding and less intracranial hemorrhage, regardless of age. |
| 2013-12-17 | Boehringer Ingelheim | Results Phase III Study of Dabigatran Etexilate Mesylate Met Primary Endpoint for Six-Month Treatment of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) prnewswire.com ↗
In this Phase III study, published online in the American Heart Association's journal Circulation, dabigatran met the primary endpoint of non-inferiority to warfarin for recurrent, symptomatic, objectively-confirmed DVT and/or PE and related deaths during six months of treatment. |
| 2013-12-10 | Daiichi Sankyo | Results Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer daiichisankyo.com ↗
Phase 3 Data Show Daiichi Sankyo’s Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer |
| 2013-11-20 | Daiichi Sankyo | Results Daiichi Sankyo´s Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial daiichisankyo.com ↗
Once-daily edoxaban also demonstrated significant reductions in major bleeding compared to warfarin, achieving superiority for the principal safety endpoint. |
| 2013-10-02 | Boehringer Ingelheim | Results New Pooled Analysis Reports Pradaxa® (dabigatran etexilate mesylate) May Be Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin prnewswire.com ↗
Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a retrospective analysis comparing clinical management and patient outcomes following a major bleeding event during treatment with dabigatran or warfarin. |
| 2013-09-13 | Basilea Pharmaceutica | Results Basilea reports presentation of 19 posters at ICAAC on investigational anti-infectives isavuconazole, ceftobiprole, and BAL30072 basilea.com ↗
No Effect on Pharmacokinetic and Pharmacodynamic Parameters of Warfarin after Coadministration with Isavuconazole |
| 2013-09-03 | Bristol-Myers Squibb | Results Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease bms.com ↗
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death |
| 2013-09-01 | Daiichi Sankyo | Results Daiichi Sankyo’s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence daiichisankyo.com ↗
Daiichi Sankyo’s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence |
| 2013-08-31 | Bristol-Myers Squibb | Results New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon bms.com ↗
The results showed that in the 30-day period following a procedure, rates of clinical events (stroke or systemic embolism, major bleeding, and all-cause death) were comparable in the Eliquis and warfarin treatment arms. |
| 2013-05-06 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation bms.com ↗
Subgroup analysis demonstrates that the treatment effects of Eliquis ® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE |
| 2013-03-18 | Boehringer Ingelheim | Results FDA Perspective Published in the New England Journal of Medicine Reinforces Safety of Pradaxa® (dabigatran etexilate mesylate) prnewswire.com ↗
The FDA stated that bleeding rates associated with new use of PRADAXA do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY ® trial. |
| 2013-02-20 | Boehringer Ingelheim | Results New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism prnewswire.com ↗
RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, including VTE-related death. |
| 2012-12-08 | Boehringer Ingelheim | Results New Sub-Analyses Report Pradaxa® (dabigatran etexilate mesylate) May Be Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin prnewswire.com ↗
These findings from the RE-LY® trial and four other Phase III trials report outcomes after a major bleed on dabigatran, despite the lack of a specific reversal agent, may be better than after a warfarin-associated bleed. |
| 2012-11-04 | Boehringer Ingelheim | Results RE-LY® Sub-Analysis Suggests Similar Safety and Efficacy With Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in NVAF Patients With and Without Diabetes prnewswire.com ↗
The results show that patients with diabetes in the RE-LY study had a higher prevalence of additional cardiovascular diseases (e.g., hypertension), and for diabetic patients with NVAF randomized to warfarin, INR was not as well-controlled. |
| 2012-10-01 | Bristol-Myers Squibb | Results ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding bms.com ↗
“These findings suggest that, due to the consistent benefit of apixaban versus warfarin, current risk-scoring systems for selecting anticoagulation therapy may be less relevant when using apixaban than they are for warfarin, at least for patients with CHADS 2 scores ≥1.” |
| 2012-06-18 | Boehringer Ingelheim | Results RE-LY Sub-Analysis Suggests Pradaxa® (dabigatran etexilate mesylate) Associated with Similar Bleeding Rates and Thromboembolic Complications in Surgery Versus Warfarin prnewswire.com ↗
In the sub-analysis, there were similar rates of bleeding between treatment groups in those undergoing urgent surgery, despite the fact that a specific reversal agent for PRADAXA is not available. |
| 2012-04-18 | Boehringer Ingelheim | Results New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial prnewswire.com ↗
A new retrospective sub-analysis of the 18,113 patient RE-LY® trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa® (dabigatran etexilate mesylate) capsules 150mg taken twice daily compared with warfarin. |
| 2011-11-14 | Boehringer Ingelheim | Results New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation prnewswire.com ↗
A new retrospective subanalysis of the RE-LY® trial found Pradaxa® (dabigatran etexilate mesylate) capsules 150mg twice daily reduced the risk of stroke and systemic embolism compared to warfarin |
| 2011-08-28 | Bristol-Myers Squibb | Results ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial bms.com ↗
In the ARISTOTLE trial, ELIQUIS as compared with warfarin significantly reduced the risk of stroke or systemic embolism by 21 percent, major bleeding by 31 percent, and mortality by 11 percent. |
| 2011-06-22 | Bristol-Myers Squibb | Results ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study bms.com ↗
In addition, ELIQUIS met the key secondary endpoints of superiority on efficacy and on ISTH (International Society on Thrombosis and Haemostasis) major bleeding compared to warfarin. |
| 2011-04-04 | Boehringer Ingelheim | Results New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation prnewswire.com ↗ |
| 2011-01-05 | Boehringer Ingelheim | Results New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion prnewswire.com ↗
Similarly, major bleeding within 30 days of cardioversion was infrequent and comparable between treatment groups (1.7%, 0.6% and 0.6%, respectively). |
| 2010-08-29 | Boehringer Ingelheim | Results Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers prnewswire.com ↗
Primary outcomes were assessed across the three treatment arms (dabigatran etexilate 110mg BID, dabigatran etexilate 150mg BID, warfarin)(1) and demonstrated: |
| 2008-12-08 | Daiichi Sankyo | Results NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION daiichisankyo.com ↗
NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION |
All press releases naming this drug 73 releases
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 436 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | warfarin | “After discharge, these patients were switched to oral low-dose warfarin for anticoagulation, with a daily dose of 1.25mg (half tablet) on dialysis days, and 2.5mg/day on...” NCT04164693 ↗418“Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles.” NCT06615596 ↗ “Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.” NCT02592317 ↗ “Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)” NCT03234114 ↗ “followed by oral anticoagulation with warfarin (target INR 2.0-3.0) or direct oral anticoagulants (DOACs) for 3-12 months as per current AHA/ASA and ESO guidelines.” NCT07548346 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “Single dose of drug cocktail: 100 milligram (mg) caffeine,10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam administered orally on Day 1 in Period 1.” NCT02688088 ↗ “Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.” NCT02017197 ↗ “subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT” PMID 21128814 ↗ Dec 2010 “the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards” NCT01674647 ↗ “Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.” NCT06975605 ↗ |
| Known as | Aldocumar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Apo-warfarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Athrombin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Athrombin-k | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Choice | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Coumadin | “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗21“Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration.” NCT00450008 ↗ “Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.” NCT06055920 ↗ “If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.” NCT01042704 ↗ “Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.” NCT00790842 ↗ “the FDA approved the label change of warfarin/Coumadin™ to recommend considering lower initial doses” NCT01006733 ↗ “Warfarin (also called Coumadin®) is an anticoagulant drug (blood thinner)” NCT00377143 ↗ “an anticoagulation medicine called warfarin (Coumadin®)” NCT00634907 ↗ “warfarin (Coumadin, Bristol Myers Squibb) for 3 months” NCT00438230 ↗ “An example of this type is Warfarin (Coumadin).” NCT02100228 ↗ “Warfarin (Coumadine): INR target \[2.0-3.0\]” NCT06045858 ↗ |
| Known as | Coumadine | “Warfarin (Coumadine): INR target \[2.0-3.0\]” NCT06045858 ↗ |
| Known as | Jantoven | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Marevan | “If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral...” NCT06449469 ↗2“We aim to determine, through mean INR difference between formulations, whether there is therapeutic equivalency between the branded warfarin sodium (Marevan®) and the generic...” NCT02017197 ↗ “comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)” NCT06145269 ↗ |
| Known as | NSC-59813 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Orfarin | “Warfarin (Orfarin®) is the most popular vitamin K antagonist” NCT04569279 ↗ |
| Known as | Panwarfin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Potassium warfarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Prothromadin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Sodium warfarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01285661 ↗ |
| Known as | Varfine | “Varfine® 5 mg (warfarin 5 mg) tablets” NCT02779348 ↗ |
| Known as | Warfarin (Coumadin, Jantoven) | “Warfarin (Coumadin, Jantoven)” NCT03465735 ↗ |
| Known as | Warfarin (Marevan) | “Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.” NCT00700895 ↗ |
| Known as | WARFARIN POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarin Sodium | “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗8“SHR0302 Tablets + probe drugs (Midazolam Maleate Tablets + Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Repaglinide Tablets) + Vitamin K1 Tablets” NCT05392127 ↗ “Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).” NCT04709094 ↗ “two tablets of warfarin sodium (5mg)” NCT07362030 ↗ “Drug: Warfarin Sodium 5 MG” NCT04235569 ↗ |
| Known as | Warfarin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | warfarin sodium tablets | “warfarin sodium tablets” NCT04164693 ↗ |
| Known as | Warfarin/Coumadin | “Warfarin/Coumadin” NCT02701062 ↗ |
| Known as | Warfarina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Warfarinum natricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Known as | Zoocoumarin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1464 ↗ |
| Action | Inhibit | “warfarin inhibits circulating clotting proteins in the blood” NCT00027066 ↗ |
| Modality | Small molecule | — CHEMBL1464 ↗ |
| Route | Oral | “oral anticoagulant therapy” NCT00000517 ↗ |
| Target | VKORC1 | “warfarin target, VKORC1” NCT02065388 ↗ |